Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The strange allure of state "right-to-try" laws.

× No keyword cloud information.

17 in total

1. Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.

Authors: Denise Meyerson
Journal: J Bioeth Inq Date: 2017-06-20 Impact factor: 1.352

Review 2. Supportive and symptomatic management of amyotrophic lateral sclerosis.

Authors: Esther V Hobson; Christopher J McDermott
Journal: Nat Rev Neurol Date: 2016-08-12 Impact factor: 42.937

3. Right to Try Requests and Oncologists' Gatekeeping Obligations.

Authors: Holly Fernandez Lynch; Ameet Sarpatwari; Robert H Vonderheide; Patricia J Zettler
Journal: J Clin Oncol Date: 2019-10-15 Impact factor: 44.544

4. Overview of FDA's Expanded Access Program for Investigational Drugs.

Authors: Jonathan P Jarow; Peter Lurie; Sarah Crowley Ikenberry; Steven Lemery
Journal: Ther Innov Regul Sci Date: 2017-03-01 Impact factor: 1.778

5. The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.

Authors: Kayte Spector-Bagdady; Kevin J Weatherwax; Misty Gravelin; Andrew G Shuman
Journal: Hastings Cent Rep Date: 2019-03 Impact factor: 2.683

6. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.

Authors: Jonathan P Jarow; Steven Lemery; Kevin Bugin; Sean Khozin; Richard Moscicki
Journal: Ther Innov Regul Sci Date: 2016-11 Impact factor: 1.778

The strange allure of state "right-to-try" laws.

1. Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.

Review 2. Supportive and symptomatic management of amyotrophic lateral sclerosis.

3. Right to Try Requests and Oncologists' Gatekeeping Obligations.

4. Overview of FDA's Expanded Access Program for Investigational Drugs.

5. The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.

6. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.

7. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.

8. Precision medicine: opportunities, possibilities, and challenges for patients and providers.

9. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

10. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.